Law360 (subscription) The two drug companies have asked Judge Forrest to throw out a Teva lawsuit over the use of a patented polypeptide in their development of an abbreviated new drug application to make their own version of the drug, which brings in about $4 billion for ... and more »
Genetic Engineering News (press release) Post-translational modifications (PTMs) collectively pertain to a phase in protein biosynthesis that involves changes in a polypeptide chain, resulting in a fully functional protein product. The completion of the Human Genome Project has generated an ...
